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AbstrAct
Objective
To systematically quantify the prevalence, severity, 
and nature of preventable patient harm across a range 
of medical settings globally.
Design
Systematic review and meta-analysis.
Data sOurces
Medline, PubMed, PsycINFO, Cinahl and Embase, 
WHOLIS, Google Scholar, and SIGLE from January 
2000 to January 2019. The reference lists of eligible 
studies and other relevant systematic reviews were 
also searched.
review methODs
Observational studies reporting preventable patient 
harm in medical care. The core outcomes were 
the prevalence, severity, and types of preventable 
patient harm reported as percentages and their 95% 
confidence intervals. Data extraction and critical 
appraisal were undertaken by two reviewers working 
independently. Random effects meta-analysis was 
employed followed by univariable and multivariable 
meta regression. Heterogeneity was quantified 
by using the I2 statistic, and publication bias was 
evaluated.
results
Of the 7313 records identified, 70 studies involving 
337 025 patients were included in the meta-analysis. 
The pooled prevalence for preventable patient harm 
was 6% (95% confidence interval 5% to 7%). A pooled 
proportion of 12% (9% to 15%) of preventable patient 
harm was severe or led to death. Incidents related to 
drugs (25%, 95% confidence interval 16% to 34%) 
and other treatments (24%, 21% to 30%) accounted 
for the largest proportion of preventable patient 
harm. Compared with general hospitals (where most 
evidence originated), preventable patient harm was 
more prevalent in advanced specialties (intensive 
care or surgery; regression coefficient b=0.07, 95% 
confidence interval 0.04 to 0.10).
cOnclusiOns
Around one in 20 patients are exposed to preventable 
harm in medical care. Although a focus on 
preventable patient harm has been encouraged by 
the international patient safety policy agenda, there 
are limited quality improvement practices specifically 
targeting incidents of preventable patient harm rather 
than overall patient harm (preventable and non-
preventable). Developing and implementing evidence-
based mitigation strategies specifically targeting 
preventable patient harm could lead to major service 
quality improvements in medical care which could 
also be more cost effective.
Introduction
Patient harm during healthcare is a leading cause 
of morbidity and mortality internationally.1 2 The 
World Health Organization defines patient harm as 
“an incident that results in harm to a patient such as 
impairment of structure or function of the body and/or 
any deleterious effect arising there from or associated 
with plans or actions taken during the provision of 
healthcare, rather than an underlying disease or 
injury, and may be physical, social or psychological 
(eg, disease, injury, suffering, disability and death).”3 
The health burden and patient experiencing 
healthcare-related patient harm has been reported 
to be comparable to chronic diseases such as 
multiple sclerosis and cervical cancer in developed 
countries, and tuberculosis and malaria in developing 
countries.4  5 Harmful patient incidents are also a 
major financial burden for healthcare systems across 
the globe. It is estimated that 10-15% of healthcare 
expenditure is consumed by the direct sequelae of 
healthcare-related patient harm.6 7
Early detection and prevention of patient harm 
in healthcare is an international policy priority.8 In 
principle, zero harm would be the ideal goal. However, 
this goal is not feasible because some harms cannot be 
avoided in clinical practice. For example, some adverse 
drug reactions which occur in the absence of any error 
in the prescription process and without the possibility 
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WhAt Is AlreAdy knoWn on thIs topIc
A better understanding of the nature of preventable patient harm has the 
potential to impact on international healthcare policy and practice
The prevalence of overall patient harm has been established by systematic 
reviews but the prevalence of preventable patient harm has received less 
attention
WhAt thIs study Adds
A meta-analysis that quantifies the prevalence, nature, and severity of 
preventable patient harm in a range of medical care settings
At least one in 20 patients are affected by preventable patient harm in medical 
care settings
Approximately 12% of preventable patient harm causes permanent disability or 
patient death and is mostly related to drug incidents, therapeutic management, 
and invasive clinical procedures
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of detection are less likely to be preventable. In recent 
years, the recognition that a proportion of patient 
harm is not preventable has increased attention to 
the notion of preventable patient harm.9 Most studies 
classify patient harm as preventable if it occurs as a 
result of an identifiable modifiable cause, and its future 
recurrence can be avoided by reasonable adaptation 
to a process, or adherence to guidelines, although 
universal consensus has not been established.10 Key 
sources of preventable patient harm could include 
the actions of healthcare professionals (errors of 
omission or commission), healthcare system failures, 
or involve a combination of errors made by individuals, 
system failures, and patient characteristics.11-14 
Strengthening the focus on preventable patient harm 
has the potential to lead to greater tangible clinical 
benefits and improved translation of patient safety 
research findings into clinical practice. Patient safety 
improvement strategies underpinned by better 
understanding of the nature of preventable patient 
harm have greater prospects of efficiency (because 
they are more specific) and implementation (because 
clinicians can readily recognise their value).10
There are several systematic reviews on overall 
patient harm across different medical settings, but none 
of these have focused on preventable patient harm.1 15-17 
We undertook a systematic review and meta-analysis 
to estimate the prevalence of preventable patient harm 
across medical settings including hospitals, various 
specialties, and in primary care. We also examined 
the severity and most commonly occurring types of 
preventable patient harm.
Methods
This systematic review was conducted and reported 
in accordance with the Reporting Checklist for Meta-
analyses of Observational Studies (MOOSE).18 The 
completed MOOSE checklist is available in eTable 1. 
eligibility criteria
We included quantitative observational studies such as 
cohort (prospective or retrospective) and cross sectional 
studies in any geographical area in any medical care 
setting (primary, secondary, and tertiary care) published 
from January 2000 onwards. We selected this start date 
because it coincides with when the published patient 
safety research began to increase in volume after the 
publication of the landmark report To Err is Human: 
Building a Safer Health System in 1999.1 5 19
The primary outcome was the prevalence of 
preventable patient harm. Patient harm (which is 
synonymous with adverse events in healthcare) is 
defined as unanticipated, unforeseen accidents (eg, 
patient injuries, care complications, or death) which 
are a direct result of the care dispensed rather than 
the patient’s underlying disease. Patient harm is 
preventable firstly, when occurring as a result of an 
identifiable and modifiable cause and secondly, when 
the prevention of future recurrence of the patient harm 
is possible with reasonable adaptation to a process and 
adherence to guidelines.10
The secondary outcomes were the severity and 
types of preventable patient harm. In accordance to 
the reporting format of the eligible studies, severity 
of preventable patient harm was classified into mild, 
moderate, and severe. Key types of preventable harm 
were drug-related, diagnostic, medical procedure-
related, and healthcare-acquired infections (definitions 
are presented in eTable 1).
We excluded the following: studies reporting data on 
harm but not on preventable patient harm; studies with 
an exclusive focus on a specific type of harm only (only 
drug-related harm) or a specific severity level of harm 
only (incidents which only resulted in readmissions or 
extended length of stay) because such estimates would 
differ from estimates based on any type or any severity 
level of preventable patient harm; and studies focused 
on specific patient populations (eg, patients with a 
particular disease) because such estimates could differ 
from estimates in the general population.
searches
We searched five electronic bibliographic databases 
from January 2000 to 27 January 2019: Medline, Cinahl, 
Embase, Pubmed, and PsycINFO. We supplemented 
these searches by screening grey literature sources 
including three databases (WHOLIS, Google Scholar, 
SIGLE), relevant reports, and conference abstracts. We 
also screened existing systematic reviews and checked 
the reference lists of eligible studies. The search 
strategy is available in eTable 3.
study selection and extraction
We exported the results of the searches to Endnote 
X8 and removed duplicates. We completed screening 
in two stages. Initially, the titles and abstracts of the 
studies were screened for eligibility. Afterwards, the 
full texts of studies initially assessed as relevant for 
the review were retrieved and checked against our 
inclusion or exclusion criteria. We devised a data 
extraction spreadsheet, after being piloted, to extract 
descriptive data on key study characteristics (eg, 
number and age of participants, research design, 
data collection, assessment of preventability) and 
quantitative outcomes (prevalence, types, and severity 
of preventable patient harm). Two independent 
researchers (KK and MP) performed the screening 
and data extraction with disagreements resolved by 
discussion within the wider team (AA, DA, RH, RK). 
The inter-rater reliability was excellent (kappa=0.88 
and 0.90).
risk of bias assessment
We evaluated the risk of bias in the studies by using 
an adapted form of the Newcastle Ottawa scale for 
cross sectional and cohort studies.20 This assessed 
the representativeness of the sample, sample size, 
response rate, ascertainment of the exposure, control 
of confounding variables, assessment of preventability, 
and appropriate statistical analysis, which provided 
a score ranging from 0 (lowest grade) to 9 (highest 
grade). A higher grade indicated a lower risk of bias. 
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For our analyses, studies scoring 7 or above were 
considered as low risk, whereas studies scoring below 
7 were considered as high risk.
analyses
Our primary outcome was the prevalence of 
preventable patient harm expressed as the proportion 
of patients with at least one preventable patient 
harmful incident and stratified according to different 
medical services. We also calculated and reported 
the median prevalence of preventable patient harm 
and interquartile ranges across all medical care 
settings. Our secondary outcomes were the severity 
and types of preventable patient harm expressed as 
proportions of the total number of preventable patient 
harmful incidents. We pooled all data in Stata 15 
by using the metaprop command.21 To improve the 
meaning and interpretation of our findings in relation 
to the prevalence, severity, and common types of 
preventable patient harm, we also present data on 
the prevalence, severity, and common types of overall 
harm (preventable and non-preventable) by using the 
same pool of studies in all analyses.
We conducted univariable and multivariable 
meta regression to test the influence of study level 
moderators on the prevalence of preventable patient 
harm using the metareg command.22 Consistent with 
the recommendations of Thompson and Higgins,23 
eight prespecified study level moderators were 
hypothesised to have an effect on the prevalence 
of preventable patient harm (medical setting, 
population, research design, assessment method 
of harm, assessment of preventability, sample size, 
risk of bias, WHO region). Moderators were selected 
and coded following consensus procedures and 
each moderator value was based on a minimum of 
eight studies.23 Covariates meeting our significance 
criterion (P<0.10) were entered into a multivariable 
meta regression model. The P<0.10 threshold was 
conservative, to avoid prematurely discounting 
potentially important explanatory variables. Because 
proportions were often expected to be small, we used 
Freeman-Tukey Double Arcsine transformation to 
stabilise the variances and then performed a random 
effects meta-analysis implementing the DerSimonian-
Laird method.24 25
Random effects models were used in all analyses 
because they are more conservative and have better 
properties in the presence of heterogeneity.26 27 
Heterogeneity was quantified by using the I2 statistic. 
Conventionally, I2 values of 25%, 50%, and 75% 
indicate low, moderate, and high heterogeneity, 
respectively.28 We inspected the symmetry of the 
funnel plots and used Egger’s test to examine for 
publication bias.29 Funnel plots were constructed 
using the metafunnel command,30 and the Egger test 
was computed using the metabias command.31
Patient and public involvement
Two patient partners, who were members of our 
research advisory panel, were involved in the 
development of our research questions and in selecting 
the outcome measures of this study. The two patients 
also provided critical feedback to the protocol of the 
systematic review and advised on the interpretation 
and dissemination of results.
results
The searches yielded 7313 citations. After we removed 
duplicates and reviewed the titles and abstracts, 6522 
articles were excluded. Of the remaining 307 studies, 
241 were excluded after reviewing the full article. A 
total of 66 studies reporting 70 independent samples 
were included in the review.17 32-98 Figure 1 shows the 
study flow for the selection process.
Descriptive characteristics
This review is based on a pooled sample of 337 025 
patients, 28 150 of who experienced harmful incidents 
and 15 419 experienced preventable harmful incidents. 
A total of 47 148 harmful incidents were identified 
in the pooled sample, 25 977 (55%) of which were 
preventable. The sample sizes ranged widely across 
studies (median 1440 patients, range 128-96 047). 
Thirty three studies (47%) were conducted in the US, 
27 (39%) in Europe, and 10 (14%) elsewhere. The 
most common study design was retrospective or cross-
sectional (n=50; 71%) followed by prospective (20; 
29%). Fifty three studies (76%) reviewed the medical 
charts of patients to detect harm, whereas 17 studies 
(24%) monitored patients over time or were based on 
self reports (eg, interviews with patients). All included 
studies assess the preventability of patient harm by 
using consensus procedures between two or more 
trained reviewers (physicians or teams of physicians 
and nurses). Fifty studies (71%) used a standardised 
Likert scale to facilitate the consensus decisions for the 
preventability of patient harm among the reviewers 
(harmful incidents assigned a score of four out of six and 
over were considered preventable).99 The remaining 
20 studies (29%) used implicit agreed criteria to reach 
consensus regarding the preventability of patient harm 
among the reviewers. Most studies were conducted in 
general hospitals involving patients from a range of 
specialties (45 studies; 64%). Twelve studies (17%) 
were conducted in advanced care specialties (intensive 
care 6 studies; surgery 6 studies), six studies (8%) in 
emergency department, four in obstetrics (6%), and 
three in primary care (4%). Except for six studies (9%), 
which were based on children and adolescents, and 
five studies on older adults (7%), the remaining 59 
studies (84%) were mainly based on adults. Further 
details of the descriptive characteristics of the included 
studies are available in eTable 2.
All 70 studies reported data on the prevalence of 
preventable patient harm and overall patient harm. 
One third of the studies (20 studies, 29%) reported 
data on the severity of preventable patient harm. Forty 
three studies (60%) reported proportions of at least 
two of the following six types of preventable patient 
harm: drug management, non-drug therapeutic 
management, diagnosis, invasive medical procedures, 
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surgical procedures, and infections acquired during 
healthcare.
risk of bias results
The Newcastle Ottawa scores for the studies ranged 
from three to nine (maximum 9, a higher score 
indicating a lower risk of bias). Twenty nine studies 
(41%) scored eight or above and were considered to be 
at low risk of bias (see full assessment in eTable 3).
meta-analysis of the prevalence of preventable 
patient harm stratified by medical settings
Table 1 shows that the pooled prevalence of 
preventable patient harm was 6% (95% confidence 
interval 5% to 7%, I2=99%) and the median prevalence 
was 5% (interquartile range 3-9%). In comparison, the 
pooled prevalence of overall harm (preventable and 
non-preventable) was 12% (95% confidence interval 
9% to 14%, I2=99%; table 1) and the median was 
10% (interquartile range 7-15%). The highest pooled 
prevalence estimate of preventable patient harm was 
reported in intensive care (18%, 95% confidence 
interval 12% to 26%, I2=96%) and surgery (10%, 7% 
to 13%, I2=97%) and the lowest in obstetrics (2%, 0% 
to 4%, I2=95%). Figure 2 presents the forest plot of the 
prevalence of preventable patient harm across medical 
care settings. 
meta-analysis of the severity and types of 
preventable patient harm
Table 1 shows the pooled proportions of the severity 
and types of preventable patient harm. The pooled 
proportion of mild harm was 49% (95% confidence 
interval 43% to 56%, I2=97%), moderate harm was 
36% (31% to 42%, I2=96%), and severe harm was 
12% (9% to 15%, I2=94%).
Drug management incidents (25%, 95% confidence 
interval 16% to 34%, I2=98%), and other therapeutic 
management incidents (24%, 21% to 30%, I2=98%), 
accounted for the highest proportion of preventable 
patient harm followed by incidents related to surgical 
procedures (23%, 9% to 38%, I2=98%), healthcare 
infections (16%, 11% to 22%, I2=98%), and diagnosis 
(16%, 11% to 21%, I2=98%).
meta-regressions exploring the variance in the 
prevalence of preventable patient harm
Table 2 shows the results of the univariable and 
multivariable analyses. The univariable analyses 
showed that the prevalence of preventable patient 
harm was higher across studies based in advanced 
table 1 | Proportions of types of preventable patient harm and overall patient harm
Outcome no
Preventable harm Overall harm
% (95% ci) i2 median (iQr) % (95% ci) i2 median (iQr)
Prevalence
 Overall 70 6 (5 to 7) 99 5 (3-9) 12 (9 to 14) 99 10 (7-15)
 Emergency department 6 3 (2 to 4) 78 3 (3-4) 5 (3 to 6) 84 5 (4-6)
 Hospitals 45 5 (4 to 6) 99 5 (3-7) 10 (9 to 12) 99 10 (7-12)
 Intensive care 6 18 (12 to 26) 96 14 (10-28) 34 (19 to 50) 99 29 (20-59)
 Obstetrics 4 2 (0 to 4) 95 NA 4 (2 to 6) 92 NA
 Primary care 3 3 (0 to 9) 0 NA 7 (3 to 10) 0 NA
 Surgery 6 10 (7 to 13) 97 9 (9-10) 20 (14 to 27) 99 22 (15-30)
Severity of patient harm
 Mild 20 49 (43 to 56) 97 45 (40-55) 50 (41 to 59) 98 49 (43-58)
 Moderate 20 36 (31 to 42) 96 38 (30-50) 36 (28 to 44) 98 36 (27-47)
 Severe 20 12 (9 to 15) 94 10 (8-19) 12 (8 to 15) 95 13 (6-17)
Types of patient harm
 Drugs 25 25 (16 to 34) 98 20 (9-35) 26 (19 to 34) 99 21 (17-30)
 Other therapeutic 17 24 (21 to 30) 98 22 (16-30) 20 (9 to 31) 98 21 (12-32)
 Procedure 20 23 (13 to 33) 98 18 (6-28) 24 (17 to 31) 98 19 (14-32)
 Surgical procedure 18 23 (9 to 38) 98 21 (8-36) 31 (20 to 42) 98 27 (16-41)
 Diagnosis 20 16 (11 to 21) 98 12 (5-22) 9 (6 to 12) 98 10 (6-11)
 Healthcare infections 14 16 (11 to 22) 98 NA 21 (15 to 28) 98 NA
The proportions for types of preventable or overall harm do not add to 100% because each figure in the table is the pooled proportion which has been 
calculated by combining (after assigning appropriate weights) proportions extracted from several independent studies using meta-analysis. Moreover, 
not all studies reported all types of preventable or overall harm and therefore it is not appropriate to assume they add up to 100%.
NA=not applicable.
Records screened aer duplicates removed
Full text articles excluded
No data on preventable
  harm
Rare conditions
Non-empirical
200
10
31
241
Records excluded
Additional records identified
through other sources
Records identified through
database searching
7313
6522
Full text articles assessed for eligibility
6215
22
307
Included studies (70 independent samples)
66
Fig 1 | Flowchart of the inclusion of studies in the review
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Fig 2 | Forest plot of the pooled prevalence of preventable patient harm across medical care settings
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specialties such as surgery and intensive care (b=0.08, 
95% confidence interval 0.05 to 0.11), in studies with 
relatively small sample sizes (b=0.03, 0.01 to 0.06), 
and in studies on children and older adults (b=0.03, 
−0.01 to 0.05). These three variables (medical care 
setting, population group, and sample size) were 
therefore eligible for inclusion in the multivariable 
regression analysis. All the other variables (research 
design, assessment method of harm, assessment of 
preventability, risk of bias, and WHO region) were 
ineligible for inclusion in multivariable analyses 
because none of them influenced the prevalence of 
preventable patient harm in unvariable analyses 
(P>0.10).
The overall multivariable model was statistically 
significant (χ2 (4)=33.98, P<0.001) and reduced the 
I2 statistic from 79% to 31%. Only the medical care 
setting (b=0.07, 95% confidence interval 0.04 to 0.10) 
remained a significant predictor of the prevalence of 
preventable patient harm in multivariable analyses 
suggesting that the prevalence of preventable patient 
harm is higher in advanced medical specialties (surgery 
and primary care) compared with studies in general 
hospitals. The population group and sample size 
were not significantly associated with the prevalence 
of preventable patient harm after controlling for the 
medical care setting in the multivariable analyses.
small study bias 
Figure 3 shows some evidence of publication bias as 
indicated by visual inspections of the funnel plots and 
by the Egger test for small study effects for the primary 
outcome (bias coefficient for the main analysis 1.20, 
95% confidence interval 0.24 to 2.15, P=0.02).
discussion
Understanding and mitigating preventable patient 
harm is a major public health challenge across the 
globe. We conducted a systematic review and meta-
analysis to understand the prevalence, severity, 
and common types of preventable patient harm 
across medical care settings. We pooled data from 
70 studies and we found that preventable patient 
harm occurs in 6% of patients across medical care 
settings. Considering that a pooled prevalence of 
12% for overall harm was found, we conclude that 
half of patient harm is preventable. The proportion of 
severe preventable patient harm causing prolonged, 
permanent disability or death was 12%. The most 
common types of preventable patient harm were 
related to drugs, other therapeutic management, 
and invasive medical and surgical procedures. The 
most extensive evidence on preventable patient harm 
comes from hospitals (45 studies) but less evidence is 
available for specific medical specialties. Preventable 
patient harm was more prevalent in patients treated 
in surgical and intensive care units compared with 
patients treated within across general hospitals. 
None of the other method variations which we 
examined across the studies influenced the pooled 
prevalence of preventable patient harm (population 
group, research design, assessment method of harm, 
assessment of preventability, sample size, risk of bias, 
or WHO region).
table 2 | univariable and multivariable predictors of the prevalence of preventable patient harm (n=70)
variable no
univariable multivariable
regression coefficient 
(95% ci) se P value
regression coefficient 
(95% ci) se P value
WHO region:
 US 33 1 — — — — —
 Europe 27 −0.01 (−0.03 to 0.01) 0.01 0.59 NA NA NA 
 Asia or other 10 −0.01 (−0.02 to 0.04) 0.02 0.54 NA NA NA 
Medical setting:
 General hospitals and obstetrics 49 1 — — 1 — — 
 Primary care and emergency department 9 −0.02 (−0.05 to 0.01) 0.02 0.18 −0.03 (−0.06 to 0.01) 0.02 0.12
 Advanced hospital specialties 12 0.08 (0.05 to 0.11) 0.02 <0.001 0.07 (0.04 to 0.10) 0.01 <0.001
Research design:
  Retrospective or cross sectional 50 1 — — — — —
  Prospective 20 0.01 (−0.01 to 0.04) 0.01 0.31 NA NA NA 
Sample size:
 Large (n>1000) 43 1 — — 1 — — 
 Small (n<1000) 27 0.03 (0.01 to 0.06) 0.01 0.02 0.02 (−0.01 to 0.04) 0.01 0.12
Population:
 Adults 59 1 — — — — —
 Children or older adults 11 0.03 (−0.01 to 0.05) 0.02 0.09 0.02 (−0.01 to 0.05) 0.01 0.09
Assessment method:
 Medical record review 53 1 — — — — —
 Surveys with patients and health providers 17 −0.01 (−0.04 to 0.02) 0.01 0.58 NA NA NA 
Preventability by consensus among reviewers using:
 Standardised Likert scale 43 1 — — 1 — — 
 Implicit criteria 27 0.01 (−0.01 to 0.04) 0.01 0.36 NA NA NA
Risk of bias:
  High (<7 score) 41 1 — — — — —
  Low (>7 score) 29 −0.01 (−0.03 to 0.02) 0.01 0.89 NA NA NA 
SE=standard error; NA=not applicable.
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strengths and limitations of the study
Despite the unique focus on preventable patient harm 
and several method strengths, this review has also 
limitations. Firstly, the prevalence of preventable 
patient harm varied considerably across studies and this 
variation was only partly explained in meta regression 
analyses. Other relevant factors likely accounted for the 
unexplained heterogeneity. For example, variations in 
the timeframe used to detect harm might be important 
when interpreting the differences in the prevalence 
estimates,1 alongside variations in the implementation 
of quality assurance programmes and the quality of the 
documentation used for detecting preventable patient 
harm. For example, quality assurance programmes 
have possibly been implemented in parallel with some 
of the reviewed studies which might account for some 
proportion of the heterogeneity that we observed in 
this meta-analysis. 
Secondly, a critical eligibility criterion to ensure 
feasibility of this review was that data on preventable 
patient harm were available in the published reports 
of the studies. Studies which did not report data on 
preventable patient harm were excluded from the 
analyses. However, most studies focused primarily 
on overall patient harm, reported preventable patient 
harm as a secondary outcome, and only one third of 
the studies provided an analysis of severity and types 
of preventable patient harm.100
Thirdly, preventability rankings are likely to 
evolve over time especially after new technological 
advancements in healthcare. Consequently, some 
patient harms which are now considered non-
preventable might be preventable in the future.10 
However, the studies we reviewed consistently found 
that about 50% of patient harm was preventable and 
we did not observe any different patterns over the past 
19 years. 
Fourthly, over half of the reviewed studies employed 
retrospective case record reviews to investigate the 
prevalence, nature, and severity of preventable patient 
harm. Although case record reviews are the most 
universally used method for assessing patient harm to 
date, patients and healthcare providers have repeatedly 
expressed concerns that data contained in case records 
do not capture the full range of harms that they 
experience during their healthcare encounters.101  102 
On the other hand, self reporting of patient harms 
(either by patients or healthcare providers) relies on 
recall and has its own limitations. Combining methods 
(such as prospective case record reviews with surveys 
with patients and healthcare providers)103 with 
the parallel engagement of patients as partners in 
identifying medical errors and mitigating preventable 
patient harm are promising approaches for enhancing 
patient safety.104 105
comparison with other studies
Our headline finding is that preventable patient harm 
is a highly prevalent international healthcare challenge 
which causes unnecessary patient suffering and can 
result in several avoidable deaths. As this review 
is specifically designed to understand patterns of 
preventable patient harm, comparisons with existing 
reviews focused on overall harm is problematic.1 15 106-
108 Although we concur that examining the nature of 
overall harm is important, increasing the emphasis on 
preventable patient harm (which is the most amenable 
form of patient harm) is critical in terms of designing 
efficient patient safety strategies. 
There is also evidence that preventable patient 
harm is not only a public health concern but incurs 
a considerable opportunity cost. The excess length 
of hospital stays attributable to medical errors is 
estimated to be 2.4 million hospital days, which 
accounts for $9.3 billion (£7.3bn; €8.2bn) excess 
charges in the US.7 Similarly, only six selected types 
of preventable patient harms in English hospitals 
result in 934 excell bed days per 100 000 population, 
which is equivalent to over 3500 salaried hospital 
nurses each year.109 Thus, investments in developing 
and evaluating mitigation strategies for preventable 
patient harm are urgently needed and are strongly 
supported by our findings.
Policy implications
Our findings provide a useful agenda of priority areas for 
mitigating preventable patient harm. When exploring 
the nature of preventable patient harm, drug related 
and therapeutic incidents comprise the majority. This 
finding echoes recommendations from international 
patient safety policy initiatives in the past decade 
including the recent WHO’s third global patient safety 
challenge “medication without harm.”106 110 Thus, it 
would be logical to prioritise efforts on developing and 
testing evidence-based mitigation strategies for these 
specific types of preventable patient harm. As this 
study establishes the scale of preventable patient harm 
in medical care settings, the need to gain better insight 
about the systemic and cultural circumstances under 
which preventable patient harm occurs is highlighted 
as a priority area. Several studies have sought to explain 
patient harms by reference to their sociotechnical 
context. For example, Vincent and colleagues proposes 
that patient harm occur because of contributory factors 
(which include “active” and “latent” failures) in the 
healthcare system.111 These failures correspond to 
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characteristics of the system such as the tasks that 
are undertaken, the people, technology, and tools 
that are involved, and the organisational values and 
structures in which the system operates.112 The studies 
included in our review, however, did not provide much 
insight into the way in which such factors might have 
contributed to the instances of preventable harm 
identified. Retrospective examination of patient harm 
often does not capture the myriad ways in which 
contributory factors could combine to produce—or 
avert—a preventable incident of patient harm.113 Mixed 
method approaches, which connect the occurrence of 
patient harm to the presence of specific contributory 
factors and engage patients as partners in establishing 
these connections, have excellent prospects to achieve 
an in depth understanding of possible pathways to 
patient harm.114-118
A thorough understanding of the nature of preventable 
patient harm and its determinants could offer useful, 
evidence-based directions for designing efficient mitigation 
strategies. A combination of individual-level measures 
(eg, educational interventions for practitioners), system-
level measures (eg, human-centred design of healthcare 
tasks and work environments), and organisational-
level measures (eg, introducing quality monitoring and 
improvement processes) are likely to be a promising 
strategy for mitigating preventable patient harm,119 120 
but scalable evaluations of these interventions are needed 
to support wider implementation. Furthermore, the 
interventions depend on the presence of an organisational 
context that supports their implementation.121 122
Another important finding is that preventable 
patient harm appears to be a serious concern in 
advanced medical specialties including intensive care 
and surgical units. Patients treated in these specialties 
were more likely to experience preventable patient 
harm compared with patients treated in general 
hospitals. Surgical harm is a sizeable part of the overall 
in-hospital harm,15 123 but our estimates are higher 
than anticipated. The underlying causes of these 
figures warrant further investigation because current 
safety standards could “be failing to rescue” many 
high risk patients treated in advanced specialties.124 
Moreover, clinicians in these specialties are often 
exposed to work pressures and are expected to 
deliver life-changing decisions quickly which might 
negatively impact on their personal wellbeing, a well 
known risk factor for preventable medical incidents.125 
On the other hand, surgery and intensive care units 
deal with high risk patients to whom complex medical 
procedures are implemented. Patient harm therefore 
might be more detectable in these settings because 
of its immediate, serious, or cumulative impact on 
patients’ health or because better surveillance systems 
for detecting patient harm are implemented in these 
settings. Additionally, it is not always clear from the 
study designs that some proportion of the preventable 
patient harm has not occurred in the transition between 
general hospital care and advanced specialty care.108
Another major contribution of our synthesis is that 
it highlights key gaps in the literature on preventable 
patient harm. Only two studies were based in primary 
care, where over 80% of healthcare service is delivered 
internationally,8 126 and no evidence was identified in 
psychiatry. Certain types of preventable harms which 
tend to occur in primary care and psychiatry might 
remain undetected or untargeted by quality and safety 
improvement programmes. For example, we found 
that diagnostic harm is a common preventable type of 
harm but our understanding of its nature needs to be 
improved. A likely explanation is that diagnostic harm 
is directly or indirectly linked with the provision of 
services in primary care where research on preventable 
patient harm is sparse.127 128 Obtaining more precise 
estimates of the types and sources of preventable 
diagnostic harm occurring in primary care or in 
transitions from primary care to hospital care could lay 
the foundation for implementing efficient interventions 
for diagnostic harm. Systemic interventions, enhanced 
patient involvement in decision making for diagnoses, 
use of electronic tools, and emotion-cognitive inter-
ventions for boosting practitioners’ confidence or 
certainty in making diagnoses are potentially fruitful 
intervention areas for reducing diagnostic harm but 
have not been systematically evaluated or implemented 
in practice.104 127-130
Less than a handful of studies focused on children 
and older adults, groups increasingly viewed as 
vulnerable to low quality or unsafe care. Furthermore, 
only a fraction of the included studies were conducted in 
developing countries, as many studies from developing 
countries failed to provide data on preventability of 
harm which rendered them ineligible. Thus, despite 
the evidence showing that the prevalence of overall 
harm is higher in developing countries compared with 
developed countries, we did not find such difference 
for preventable patient harm. 
Commissioning research to understand the prevalence, 
nature, and impact of preventable patient harm in 
primary care and psychiatry, among vulnerable patient 
groups (eg, young children, older adults, or marginalised 
groups of the society such prison healthcare) and in 
developing countries has the potential to advance policy 
guidance and practice for mitigating preventable patient 
harm.
conclusion
Our findings affirm that preventable patient harm is a 
serious problem across medical care settings. Priority 
areas are the mitigation of major sources of preventable 
patient harm (such as drug incidents) and greater 
focus on advanced medical specialties. It is equally 
imperative to build evidence across specialties such 
as primary care and psychiatry, vulnerable patient 
groups, and developing countries. Improving the 
assessment and reporting standards of preventability 
in future studies is critical for reducing patient harm in 
medical care settings.
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